Screener
BioMarin Pharmaceuticals BMRN Royalty and other revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| REVENUES: | ||||
| Net product revenues | $984,393 | $812,982 | $1,744,471 | $1,547,626 |
| Royalty and other revenues | 5,315 | 12,428 | 11,445 | 22,929 |
| Total revenues | 989,708 | 825,410 | 1,755,916 | 1,570,555 |
| OPERATING EXPENSES: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| Research and development | 206,952 | 161,308 | 385,748 | 320,039 |
| Selling, general and administrative | 395,549 | 232,279 | 653,839 | 438,395 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's royalty and other revenues — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported royalty and other revenues — total revenues of $5.32M in Q2 2026.
- How has BioMarin Pharmaceuticals's royalty and other revenues — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's royalty and other revenues — total revenues decreased by 57.2% year-over-year, from $12.43M to $5.32M.
- What is the long-term trend for BioMarin Pharmaceuticals's royalty and other revenues — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's royalty and other revenues — total revenues has grown at a -3.9% compound annual growth rate (CAGR), from $62.78M to $53.49M.
- What does royalty and other revenues — total revenues mean?
- This metric represents the total revenue generated from royalty payments, licensing agreements, and other miscellaneous commercial activities outside of direct product sales. It captures income streams derived from intellectual property rights or partnerships where the company receives a percentage of sales or milestone payments from third-party distributors. This segment is critical for assessing the company's ability to monetize its research and development pipeline through indirect commercialization channels.
Ask your AI about BioMarin Pharmaceuticals's royalty and other revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude